TY - JOUR
T1 - Phase II study of carboplatin, cisplatin, and vindesine in advanced non-small-cell lung cancer
AU - Saito, Hiroshi
AU - Shimokata, Kaoru
AU - Saka, Hideo
AU - Yamamoto, Masashi
AU - Ogasawara, Tomohiko
AU - Nomura, Fumio
AU - Sakai, Shuzo
AU - Iwata, Masamitsu
AU - Murate, Takanao
AU - Miyachi, Takuya
AU - Nakashima, Kazumitsu
AU - Saito, Hidehiko
PY - 1993/3
Y1 - 1993/3
N2 - Cisplatin in combination with vindesine has been widely used for the treatment of advanced non-small-cell lung cancer (NSCLC), producing an overall response rate of 32%. We conducted a phase II study to examine whether the addition of carboplatin to the combination of cisplatin and vindesine would improve the antitumor activity of the two platinum agents in advanced NSCLC without increasing their toxicity. Carboplatin (240 mg/m2) and vindesine (3 mg/m2) were given intravenously on day 1 and cisplatin (60 mg/m2) and vindesine (3 mg/m2), on day 8. Of the 40 evaluable patients with advanced NSCLC, 12 showed a partial response, for an overall response rate of 30% (95% confidence interval, 17%-47%). The median duration of response was 12 weeks, and the median survival duration for all patients was 38 weeks. The major toxicity was hematologic: leukopenia (WHO grade≥3) was observed in 21 patients (53%) and anemia (WHO grade≥3), in 13 patients (33%). However, thrombocytopenia was mild and WHO grade 3 toxicity was observed in only 4 patients (10%). Nonhematologic toxicities consisted mainly of WHO grade≥2 nausea and vomiting in 16 patients (40%) and WHO grade≥2 alopecia in 11 patients (28%). No significant nephrotoxicity or neurotoxicity was seen. Our findings indicate that the addition of carboplatin to the combination of cisplatin and vindesine does not improve antitumor activity in patients with advanced NSCLC.
AB - Cisplatin in combination with vindesine has been widely used for the treatment of advanced non-small-cell lung cancer (NSCLC), producing an overall response rate of 32%. We conducted a phase II study to examine whether the addition of carboplatin to the combination of cisplatin and vindesine would improve the antitumor activity of the two platinum agents in advanced NSCLC without increasing their toxicity. Carboplatin (240 mg/m2) and vindesine (3 mg/m2) were given intravenously on day 1 and cisplatin (60 mg/m2) and vindesine (3 mg/m2), on day 8. Of the 40 evaluable patients with advanced NSCLC, 12 showed a partial response, for an overall response rate of 30% (95% confidence interval, 17%-47%). The median duration of response was 12 weeks, and the median survival duration for all patients was 38 weeks. The major toxicity was hematologic: leukopenia (WHO grade≥3) was observed in 21 patients (53%) and anemia (WHO grade≥3), in 13 patients (33%). However, thrombocytopenia was mild and WHO grade 3 toxicity was observed in only 4 patients (10%). Nonhematologic toxicities consisted mainly of WHO grade≥2 nausea and vomiting in 16 patients (40%) and WHO grade≥2 alopecia in 11 patients (28%). No significant nephrotoxicity or neurotoxicity was seen. Our findings indicate that the addition of carboplatin to the combination of cisplatin and vindesine does not improve antitumor activity in patients with advanced NSCLC.
UR - http://www.scopus.com/inward/record.url?scp=0027484225&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027484225&partnerID=8YFLogxK
U2 - 10.1007/BF00685334
DO - 10.1007/BF00685334
M3 - Article
C2 - 8261575
AN - SCOPUS:0027484225
SN - 0344-5704
VL - 33
SP - 154
EP - 156
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
IS - 2
ER -
